Physician profile
Justin Fields
NPI 1003013723
$1,230.81
in general payments reported to CMS, 2019-2025
24 companies · $518 in 2025
The $518 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $23.00 · 2022: $113 · 2023: $296 · 2024: $280 · 2025: $518.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,094.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $185.45 | 2022-2025 | |
| Sumitomo Pharma America, INC. | $125.28 | 2023-2025 | Gemtesa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.17 | 2023-2025 | Jardiance |
| Glaxosmithkline, LLC. | $117.99 | 2023-2025 | Shingrix, Arexvy |
| Pfizer INC. | $106.73 | 2023-2025 | |
| Vanda Pharmaceuticals INC. | $86.29 | 2024-2025 | Fanapt |
| Amgen INC. | $62.65 | 2023-2025 | Repatha, Repatha, Otezla |
| Lilly USA, LLC | $62.50 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Dexcom, INC. | $41.91 | 2023-2025 | Dexcom G6 Transmitter |
| Sanofi Pasteur INC. | $40.66 | 2024-2025 | |
| Dynavax Technologies Corporation | $36.37 | 2024 | Heplisav-B |
| Exact Sciences Corporation | $31.63 | 2023 | Cologuard Collection Kit |
| Boston Scientific Corporation | $25.30 | 2025 | Watchman Access System |
| Senseonics, Incorporated | $23.00 | 2020 | |
| Inspire Medical Systems, INC. | $21.94 | 2025 | Inspire |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $21.80 | 2023 | |
| Almatica Pharma LLC | $20.43 | 2025 | Teriparatide |
| Catalyst Pharmaceuticals, INC. | $20.35 | 2024 | |
| Ge Healthcare | $17.22 | 2023 | |
| Merck Sharp & Dohme LLC | $16.77 | 2024 | Gardasil 9, Capvaxive, Gardasil |
| Amneal Pharmaceuticals LLC | $15.48 | 2025 | Unithroid |
| Novo Nordisk INC | $14.70 | 2025 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.19 | 2024 | Xifaxan |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$279,651.34 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Fields listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.